Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ604604,5-0,49
KB681,5683,50,07
PKN71,6271,68-0,14
Msft243,43243,890,00
Nokia4,0654,069-2,67
IBM143144,310,00
Daimler AG71,6971,71-2,79
PFE39,6839,730,00
11.05.2021 10:15:50
Indexy online
AD Index online
select
AD Index online
 

  • 11.05.2021 10:09:13
Ipsen (IPN.PA, Paris)
Poslední obchod Změna (%) Změna (EUR) Objem obchodů (EUR)
78,58 -1,85 -1,48 2 873 920
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 11.05.2021
Popis společnosti
Obecné informace
Název společnostiIpsen SA
TickerIPN
Kmenové akcie:Ordinary Shares
RICIPN.PA
ISINFR0010259150
Poslední známé roční výsledky31.12.2020
Poslední známé čtvrtletní výsledky31.03.2021
Počet zaměstnanců k 31.12.2020 5 703
Akcie v oběhu k 31.12.2020 82 964 839
MěnaEUR
Kontaktní informace
Ulice65 Quai Georges Gorse
MěstoBOULOGNE-BILLANCOURT
PSČ92100
ZeměFrance
Kontatní osoba 
Funkce kontaktní osoby 
Telefon33 158 335 000
Fax33158335001

Business Summary: Ipsen SA is a France-based biopharmaceutical group specialized in specialty care. The Company operates globally through two segments: Specialty Care and Consumer Healthcare. In Specialty Care, the Company is focused on various therapeutic areas, including oncology, neurosciences and rare diseases. Its oncology portfolio includes Somatuline, Decapeptyl, Cabometyx and Onivyde. Its neuroscience portfolio includes Dysport, and in rare diseases key products are NutropinAq and Increlex. Its primary care portfolio includes Smecta, Forlax, Fortrans, Eziclen, and Tanakan. In oncology Ipsen focuses on a number of disease areas, which include neuroendocrine tumors, renal cell carcinoma, hepatocellular carcinoma and pancreatic cancer. In addition, the Company has specialism in neurotoxin research and operates three research and development centers located in France, the United Kingdom and the United States.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2020, Ipsen SArevenues remained flat at EUR2.69B. Net income applicableto common stockholders excluding extraordinary itemstotaled EUR544.2M vs. loss of EUR54.9M. Revenues reflectOncology segment increase of 7% to EUR1.97B, North Americasegment increase of 10% to EUR857.6M, United Kingdomsegment increase of 10% to EUR116.2M, also reflect PrimaryCare segment decrease of 24% to EUR210.6M.
Odvětvová klasifikace
TRBC2012Pharmaceuticals - NEC
RBSS2004Pharmaceuticals - Diversified
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICS2007Biological Product (exc Diagnostic) Mfg
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
NAICS1997Biological Product (except Diagnostic) Manufacturing
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICBiological Prod's Not Diagnostic
SICPharmaceutical Preparations
SICCommercial Physical Research



  • Poslední aktualizace: 11.05.2021
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the BoardMarc de Garidel6218.07.201622.11.2010
Chief Executive Officer, DirectorDavid Loew5301.07.202001.07.2020
Vice Chairman of the BoardAntoine Flochel5530.08.200530.08.2005
Chief Financial Officer, Executive Vice PresidentAymeric le Chatelier5101.07.202003.11.2014
Chief Human Resource Officer, Executive Vice PresidentRegis Mulot5413.03.201813.03.2018
Executive Vice President, Chief Ethics and Compliance OfficerDominique Laymand6506.10.201701.01.2015
Executive Vice President, General CounselFrancois Garnier58
Executive Vice President, Strategy and TransformationDominique Bery4913.03.201813.03.2018
Executive Vice President and President, Consumer HealthcareBenoit Hennion44
Executive Vice President, Chief Medical OfficerSteven Hildemann-01.03.202001.03.2020